Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y₁₂ receptor antagonist

Click to increase image sizeClick to decrease image size

Declaration of interest

RF Storey reports institutional research grants/support from AstraZeneca, GlyCardial Diagnostics and Thromboserin; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, GlyCardial Diagnostics, Haemonetics, Portola, and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, and Medscape. In addition, RF Storey was the Chief Investigator for the phase IIa study of selatogrel (unpaid). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

WAE Parker is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/18/49/33752).